Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
57,48 BRL | 0,00% | +2,19% | +15,08% |
09/05 | AMGEN INC. : Redburn Atlantic handhaaft het Neutraal advies | ZM |
08/05 | AMGEN INC. : Mizuho Securities geeft koopadvies | ZM |
Vakgebied
- geneesmiddelenverkoop (94,2%): geneesmiddelen voor de behandeling van kanker, stofwisselingsstoornissen, botziekten, nierfalen, hemofilie, enz;
- overige (5,8%): voornamelijk royalty's.
De Verenigde Staten zijn goed voor 70,3% van de netto-omzet.
Aantal werknemers: 26 700
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8,50% |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15,90% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6,51% |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8,91% |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35,62% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01-06-06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23-10-19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01-01-07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01-01-15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-01-05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-06-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03-02-17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14-10-16 |
Robert Williams
BRD | Director/Board Member | 75 | 17-10-14 |
Robert Eckert
BRD | Director/Board Member | 69 | 01-01-03 |
Ronald Sugar
BRD | Director/Board Member | 75 | 22-07-10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01-06-06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24-10-17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01-01-12 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30-07-21 |
Greg Garland
BRD | Director/Board Member | 66 | 16-10-13 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 536 434 692 | 535 106 546 ( 99,75 %) | 0 | 99,75 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
BEIGENE, LTD. 19.82% | 246 269 426 | 19.82% | 2 992 444 422 $ |
4 910 000 | 5.50% | 116 121 500 $ | |
VIGIL NEUROSCIENCE, INC. 8.69% | 3 206 281 | 8.69% | 10 933 418 $ |
100 993 | 0.67% | 2 965 154 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the private company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The private company is located in Bermuda. |
Biotechnology
|
Amgen Manufacturing Ltd. (Bermuda)
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
-2,71% | 159 mld. |
- Beurs
- Aandelen
- Koers AMGN
- Koers AMGN34
- Onderneming Amgen Inc.